未登录

K

Kathryn Balmanno

uk research & innovation (ukri)

H指数:28

被引数:3,895

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Modeling human embryo implantation in vitro

体外人胚胎着床建模

IF42.5

2025-12-230

OAAI

ERK1/2 inhibitors act as monovalent degraders inducing ubiquitylation and proteasome-dependent turnover of ERK2, but not ERK1

BIOCHEMICAL JOURNAL

IF4.3

2023-05-045

OAAI

ΔRaf-1:ER* bypasses the cyclic AMP block of extracellular signal-regulated kinase 1 and 2 activation but not CDK2 activation or cell cycle reentry

MOLECULAR AND CELLULAR BIOLOGY

IF2.7

2023-03-2722

OAAI

IKKα plays a major role in canonical NF-KB signalling in colorectal cells

BIOCHEMICAL JOURNAL

IF4.3

2022-02-0417

OAAI

Dual-Mechanism ERK1/2 Inhibitors Exploit a Distinct Binding Mode to Block Phosphorylation and Nuclear Accumulation of ERK1/2

MOLECULAR CANCER THERAPEUTICS

IF5.5

2020-02-0620

OAAI

An mTORC1-to-CDK1 Switch Maintains Autophagy Suppression during Mitosis

有丝分裂过程中mTORC1-to-CDK1开关维持自噬抑制

IF16.6

2020-01-0171

OAAI

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance

NATURE COMMUNICATIONS

IF15.7

2019-05-0243

OAAI

Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome

CELLULAR AND MOLECULAR LIFE SCIENCES

IF6.2

2015-09-0730

OAAI

Adaptation to chronic mTOR inhibition in cancer and in aging

BIOCHEMICAL SOCIETY TRANSACTIONS

IF4.3

2013-07-1811

PREAI

Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation

JOURNAL OF CELL SCIENCE

IF3.6

2013-01-0178

OAAI

Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance

IF7.3

2012-08-06131

OA

Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling

BIOCHEMICAL SOCIETY TRANSACTIONS

IF4.3

2012-01-1923

PREAI

Regulation of MEK/ERK pathway output by subcellular localization of B-Raf

B-raf亚细胞定位对MEK/ERK通路输出的调控

BIOCHEMICAL SOCIETY TRANSACTIONS

IF4.3

2012-01-1925

PREAI

CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIMEL

BIMEL的有丝分裂磷酸化需要CDK1，而不是ERK1/2或ERK5

CELLULAR SIGNALLING

IF3.7

2012-01-0122

PREAI

Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells (vol 4, art no ra17, 2011)

SCIENCE SIGNALING

IF6.6

2011-04-267

PREAI

Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells

SCIENCE SIGNALING

IF6.6

2011-03-29179

PREAI

Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics

IF4.2

2009-10-08106

PREAI

Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERKI/2 signalling and/or strong P13K signalling in colorectal cancer cell lines

INTERNATIONAL JOURNAL OF CANCER

IF4.7

2009-09-18135

PREAI

ERK1/2 and p38 cooperate to delay progression through G1 by promoting cyclin D1 protein turnover

ERK1/2和p38通过促进细胞周期蛋白D1蛋白周转来协同延缓G1进程

CELLULAR SIGNALLING

IF3.7

2008-11-0119

PREAI

Tumour cell survival signalling by the ERK1/2 pathway

CELL DEATH AND DIFFERENTIATION

IF15.4

2008-10-10460

OAAI